Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2008

View Archived Issues

New compounds for the treatment of cancer disclosed in recent patent literature

Genetic variations may influence golimumab efficacy in severe asthma

Mepolizumab investigated in eosinophilic esophagitis and nasal polyposis

AGI completes optimization phase of development of AGI-010 for nocturnal acid breakthrough

DiObex and Camurus to develop DIO-901 using FluidCrystal technology

Tetravalent dengue fever vaccine safe and immunogenic in Flavivirus-naive children

Studies elucidate role of smooth muscle PPARgamma in cardiovascular function

Molecular processes identified in anxiety and alcoholism comorbidity

Diamyd receives Swiss approval to commence phase III diabetes vaccine studies

Lipsovir shown to prevent cold sores in phase III trial

Peptimmune completes phase I novel peptide copolymer trial in MS

NanoBio reports positive phase IIb results for NB-001 in herpes labialis

Onyvax completes enrollment in European phase IIb Onyvax-P trial

MEDI-528 begins phase IIa study for asthma

AEG-33773 enters clinical testing for diabetic neuropathic pain

Oramed cleared for phase IIa study of oral insulin

ReNeuron updates strategy for ReN-001

Axis-Shield HbA1c test approved by FDA

Recent Emisphere patent describes novel drug delivery agents

Epix discontinues PRX-00023 development and provides pipeline update

Novel agents for autoimmune diseases reported in recent Novartis patent

Genzyme withdraws EU application to extend Evoltra and plans to resubmit

Mifamurtide now available through compassionate access study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...